BRAF and acute lymphoblastic leukemia: Consistently, either PTCs harboring BRAF + TERT, or a BRAF mutation (either alone or in combination with TERT, ALL BRAF) or PTCs harboring any mutation (ALL MUT) showed significantly increased ROS production compared with non-mutated PTCs (p = 0.03, 0.01, 0.02, respectively).